The Global Vascular Closure Device Market was valued at USD 1.74 billion in 2024 and is estimated to grow at a CAGR of 5.7% to reach USD 3 billion by 2034.
This growth can be attributed to several factors, including the rising prevalence of cardiovascular diseases, the growth of interventional cardiology and radiology procedures, and the increasing demand for outpatient and same-day discharge procedures. Vascular closure devices are essential medical tools designed to seal arterial punctures after catheterization procedures, either using mechanical clips, sutures, or collagen plugs. These devices offer quicker and more efficient hemostasis compared to traditional methods like manual compression, reducing the time needed for bleeding cessation and minimizing patient downtime. As cardiovascular diseases like coronary artery disease and heart failure rise globally, more angiographies and interventional procedures are performed, further driving the demand for vascular closure devices. Additionally, innovations such as bioabsorbable closure devices and extravascular sealing systems have expanded the adoption of VCDs by addressing complications like bleeding and infection, which improves patient outcomes and accelerates market growth.
The active vascular closure devices segment held 59.3% share in 2024, owing to their superior efficacy, faster hemostasis times, and lower complication rates. Active VCDs, including suture-based and collagen-based devices, are increasingly preferred by physicians for their ability to close vascular access sites, enabling faster recovery and more efficient catheterization procedures. This segment is expected to maintain its leadership as it allows for improved cath lab performance and shorter operation times.
The radial artery segment will grow at a CAGR of 4.4% during 2025-2034. Radial access is becoming the preferred choice in interventional cardiology because it carries a lower risk of bleeding complications and allows for faster recovery compared to femoral access. The increasing number of radial artery procedures performed in healthcare settings is driving the demand for specialized closure devices in this area.
North America Vascular Closure Device Market held a 44.9% share in 2024. The presence of advanced healthcare infrastructure, cutting-edge catheterization labs, and highly skilled interventional cardiologists contributes to the widespread acceptance and use of advanced VCDs, such as suture-mediated and collagen-based devices. The trend towards minimally invasive cardiovascular procedures, designed to shorten recovery times and reduce healthcare costs, further boosts the demand for these devices.
Key players in the Global Vascular Closure Device Market include Medtronic, Teleflex, MERIT MEDICAL, Abbott, Rex Medical, Cordis, Ensite Vascular, Terumo, HAEMONETICS, Vivasure Medical, Transluminal Technologies, Vasorum, Tricol Biomedical, and Meril. To solidify their market position, companies in the Global Vascular Closure Device Market focus on enhancing product innovation and improving patient outcomes. Many companies are investing in the development of advanced, minimally invasive technologies that reduce complications and recovery times. Strategic partnerships and collaborations with healthcare providers and research institutions are also common to expand market reach and gain clinical validation.
This product will be delivered within 2-4 business days.
This growth can be attributed to several factors, including the rising prevalence of cardiovascular diseases, the growth of interventional cardiology and radiology procedures, and the increasing demand for outpatient and same-day discharge procedures. Vascular closure devices are essential medical tools designed to seal arterial punctures after catheterization procedures, either using mechanical clips, sutures, or collagen plugs. These devices offer quicker and more efficient hemostasis compared to traditional methods like manual compression, reducing the time needed for bleeding cessation and minimizing patient downtime. As cardiovascular diseases like coronary artery disease and heart failure rise globally, more angiographies and interventional procedures are performed, further driving the demand for vascular closure devices. Additionally, innovations such as bioabsorbable closure devices and extravascular sealing systems have expanded the adoption of VCDs by addressing complications like bleeding and infection, which improves patient outcomes and accelerates market growth.
The active vascular closure devices segment held 59.3% share in 2024, owing to their superior efficacy, faster hemostasis times, and lower complication rates. Active VCDs, including suture-based and collagen-based devices, are increasingly preferred by physicians for their ability to close vascular access sites, enabling faster recovery and more efficient catheterization procedures. This segment is expected to maintain its leadership as it allows for improved cath lab performance and shorter operation times.
The radial artery segment will grow at a CAGR of 4.4% during 2025-2034. Radial access is becoming the preferred choice in interventional cardiology because it carries a lower risk of bleeding complications and allows for faster recovery compared to femoral access. The increasing number of radial artery procedures performed in healthcare settings is driving the demand for specialized closure devices in this area.
North America Vascular Closure Device Market held a 44.9% share in 2024. The presence of advanced healthcare infrastructure, cutting-edge catheterization labs, and highly skilled interventional cardiologists contributes to the widespread acceptance and use of advanced VCDs, such as suture-mediated and collagen-based devices. The trend towards minimally invasive cardiovascular procedures, designed to shorten recovery times and reduce healthcare costs, further boosts the demand for these devices.
Key players in the Global Vascular Closure Device Market include Medtronic, Teleflex, MERIT MEDICAL, Abbott, Rex Medical, Cordis, Ensite Vascular, Terumo, HAEMONETICS, Vivasure Medical, Transluminal Technologies, Vasorum, Tricol Biomedical, and Meril. To solidify their market position, companies in the Global Vascular Closure Device Market focus on enhancing product innovation and improving patient outcomes. Many companies are investing in the development of advanced, minimally invasive technologies that reduce complications and recovery times. Strategic partnerships and collaborations with healthcare providers and research institutions are also common to expand market reach and gain clinical validation.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2024
Chapter 5 Market Estimates and Forecast, by Device Type, 2021-2034 ($ Mn)
Chapter 6 Market Estimates and Forecast, by Access, 2021-2034 ($ Mn)
Chapter 7 Market Estimates and Forecast, by End Use, 2021-2034 ($ Mn)
Chapter 8 Market Estimates and Forecast, by Region, 2021-2034 ($ Mn)
Chapter 9 Company Profiles
Companies Mentioned
The companies profiled in this Vascular Closure Device market report include:- Abbott
- Cordis
- Ensite Vascular
- HAEMONETICS
- Medtronic
- Meril
- MERIT MEDICAL
- Rex Medical
- Teleflex
- TERUMO
- Transluminal Technologies
- Tricol Biomedical
- TZ Medical
- Vasorum
- Vivasure Medical
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | October 2025 |
| Forecast Period | 2024 - 2034 |
| Estimated Market Value ( USD | $ 1.74 Billion |
| Forecasted Market Value ( USD | $ 3 Billion |
| Compound Annual Growth Rate | 5.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 16 |
